<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Terns Pharmaceuticals, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/terns-pharmaceuticals-inc</link>
    <description>Latest news and press releases for Terns Pharmaceuticals, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 05 May 2026 12:45:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/terns-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c92678dffbe2df11c2b1.webp</url>
      <title>Terns Pharmaceuticals, Inc.</title>
      <link>https://6ix.com/company/terns-pharmaceuticals-inc</link>
    </image>
    <item>
      <title>Merck Completes Acquisition of Terns Pharmaceuticals, Inc.</title>
      <link>https://6ix.com/company/terns-pharmaceuticals-inc/news/merck-completes-acquisition-of-terns-pharmaceuticals-inc-1</link>
      <guid isPermaLink="true">https://6ix.com/company/terns-pharmaceuticals-inc/news/merck-completes-acquisition-of-terns-pharmaceuticals-inc-1</guid>
      <pubDate>Tue, 05 May 2026 12:45:00 GMT</pubDate>
      <description>RAHWAY, N.J., May 05, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. (&quot;Terns&quot;) (Nasdaq: TERN).</description>
    </item>
    <item>
      <title>Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia</title>
      <link>https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-pharmaceuticals-announces-fda-breakthrough-therapy-designation-granted-to-tern-701-for-certain-patients-with-chronic-myeloid-leukemia</link>
      <guid isPermaLink="true">https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-pharmaceuticals-announces-fda-breakthrough-therapy-designation-granted-to-tern-701-for-certain-patients-with-chronic-myeloid-leukemia</guid>
      <pubDate>Mon, 27 Apr 2026 12:05:00 GMT</pubDate>
      <description>Designation for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase (CP) without the T315I mutation previously treated with two or more tyrosine kinase inhibitors (TKIs)FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy D</description>
    </item>
    <item>
      <title>Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.</title>
      <link>https://6ix.com/company/terns-pharmaceuticals-inc/news/merck-announces-expiration-of-hart-scott-rodino-act-waiting-period-to-acquire-terns-pharmaceuticals-inc-1</link>
      <guid isPermaLink="true">https://6ix.com/company/terns-pharmaceuticals-inc/news/merck-announces-expiration-of-hart-scott-rodino-act-waiting-period-to-acquire-terns-pharmaceuticals-inc-1</guid>
      <pubDate>Fri, 24 Apr 2026 10:45:00 GMT</pubDate>
      <description>RAHWAY, N.J., April 24, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (&quot;HSR&quot;), in connection with Merck’s pending acquisition of Terns Pharmaceuticals, Inc. (&quot;Terns&quot;) (Nasdaq: TERN) expired at 11:59 p.m., Eastern Time, on April 23, 2026.</description>
    </item>
    <item>
      <title>Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.</title>
      <link>https://6ix.com/company/terns-pharmaceuticals-inc/news/merck-begins-tender-offer-to-acquire-terns-pharmaceuticals-inc-1</link>
      <guid isPermaLink="true">https://6ix.com/company/terns-pharmaceuticals-inc/news/merck-begins-tender-offer-to-acquire-terns-pharmaceuticals-inc-1</guid>
      <pubDate>Tue, 07 Apr 2026 13:00:00 GMT</pubDate>
      <description>RAHWAY, N.J., April 07, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Terns Pharmaceuticals, Inc. (&quot;Terns&quot;) (Nasdaq: TERN). On March 25, 2026, Merck announced that it had entered into a definitive agreement to acquire Terns.</description>
    </item>
    <item>
      <title>Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)</title>
      <link>https://6ix.com/company/terns-pharmaceuticals-inc/news/merck-to-acquire-terns-pharmaceuticals-inc-expanding-its-hematology-pipeline-with-tern-701-a-novel-candidate-for-chronic-myeloid-leukemia-cml-1</link>
      <guid isPermaLink="true">https://6ix.com/company/terns-pharmaceuticals-inc/news/merck-to-acquire-terns-pharmaceuticals-inc-expanding-its-hematology-pipeline-with-tern-701-a-novel-candidate-for-chronic-myeloid-leukemia-cml-1</guid>
      <pubDate>Wed, 25 Mar 2026 10:48:00 GMT</pubDate>
      <description>Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML Merck to hold investor call at 8 a.m. EDT today RAHWAY, N.J. and FOSTER CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that the companies have ent</description>
    </item>
    <item>
      <title>Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)</title>
      <link>https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-pharmaceuticals-reports-inducement-grants-210500966</link>
      <guid isPermaLink="true">https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-pharmaceuticals-reports-inducement-grants-210500966</guid>
      <pubDate>Mon, 02 Feb 2026 21:05:00 GMT</pubDate>
      <description>FOSTER CITY, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of February 1, 2026 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were mad</description>
    </item>
    <item>
      <title>Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-pharmaceuticals-highlight-2026-priorities-210500860</link>
      <guid isPermaLink="true">https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-pharmaceuticals-highlight-2026-priorities-210500860</guid>
      <pubDate>Wed, 07 Jan 2026 21:05:00 GMT</pubDate>
      <description>CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and expanded CARDINAL data by 2H26, and initiation of 2L+ pivotal trial in late 2026/early 2027 TERN-701 was granted U.S. FDA Fast Track designation for the treatment of CML in Q4 2025 Year-end 2025 unaudited cash, cash equivalents and marketable securities of approximately $1.0 billion, expected to pro</description>
    </item>
    <item>
      <title>Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares</title>
      <link>https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-announces-closing-public-offering-common-stock-including-full-exercise</link>
      <guid isPermaLink="true">https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-announces-closing-public-offering-common-stock-including-full-exercise</guid>
      <pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
      <description>FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology</description>
    </item>
    <item>
      <title>Terns Announces Pricing of Upsized $650 Million Public Offering</title>
      <link>https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-announces-pricing-upsized-650-million-public-offering-2025-12-10</link>
      <guid isPermaLink="true">https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-announces-pricing-upsized-650-million-public-offering-2025-12-10</guid>
      <pubDate>Tue, 09 Dec 2025 05:00:00 GMT</pubDate>
      <description>FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology</description>
    </item>
    <item>
      <title>Terns Announces Proposed Public Offering</title>
      <link>https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-announces-proposed-public-offering-2025-12-09</link>
      <guid isPermaLink="true">https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-announces-proposed-public-offering-2025-12-09</guid>
      <pubDate>Tue, 09 Dec 2025 05:00:00 GMT</pubDate>
      <description>FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology</description>
    </item>
    <item>
      <title>Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701’s Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting</title>
      <link>https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-highlights-additional-positive-phase-1-clinical-data-supporting-tern-701s-best</link>
      <guid isPermaLink="true">https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-highlights-additional-positive-phase-1-clinical-data-supporting-tern-701s-best</guid>
      <pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
      <description>64% MMR achievement by 24 weeks across all efficacy evaluable patients 75% MMR achievement by 24 weeks in efficacy evaluable patients at doses &gt;320mg QD</description>
    </item>
    <item>
      <title>Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London</title>
      <link>https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-pharmaceuticals-participate-jefferies-global-healthcare-conference-london-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-pharmaceuticals-participate-jefferies-global-healthcare-conference-london-2025</guid>
      <pubDate>Fri, 14 Nov 2025 05:00:00 GMT</pubDate>
      <description>FOSTER CITY, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology</description>
    </item>
    <item>
      <title>Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates</title>
      <link>https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides</link>
      <guid isPermaLink="true">https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides</guid>
      <pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
      <description>Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract Upcoming ASH oral presentation to</description>
    </item>
    <item>
      <title>Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting</title>
      <link>https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-announces-abstract-positive-clinical-data-tern-701-relapsed-refractory-cml</link>
      <guid isPermaLink="true">https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-announces-abstract-positive-clinical-data-tern-701-relapsed-refractory-cml</guid>
      <pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
      <description>Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at</description>
    </item>
    <item>
      <title>Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity</title>
      <link>https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-pharmaceuticals-reports-topline-12-week-data-its-phase-2-trial-evaluating-oral</link>
      <guid isPermaLink="true">https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-pharmaceuticals-reports-topline-12-week-data-its-phase-2-trial-evaluating-oral</guid>
      <pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
      <description>Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse events Asymptomatic, reversible grade 3 liver</description>
    </item>
    <item>
      <title>Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025</title>
      <link>https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-pharmaceuticals-host-educational-webinar-tern-701-investors-advance-phase-1</link>
      <guid isPermaLink="true">https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-pharmaceuticals-host-educational-webinar-tern-701-investors-advance-phase-1</guid>
      <pubDate>Thu, 21 Aug 2025 04:00:00 GMT</pubDate>
      <description>Webinar to be held on Wednesday, September 3, 2025 at 4:30 p.m. ET FOSTER CITY, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns”</description>
    </item>
    <item>
      <title>Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates</title>
      <link>https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides</link>
      <guid isPermaLink="true">https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides</guid>
      <pubDate>Tue, 05 Aug 2025 04:00:00 GMT</pubDate>
      <description>Phase 1 trial of TERN-701 in chronic myeloid leukemia (CML) enrolling well; efficacy and safety data including 6-month major molecular response (MMR) rates</description>
    </item>
    <item>
      <title>Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions</title>
      <link>https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-pharmaceuticals-presents-positive-data-phase-1-study-tern-601-once-daily-oral</link>
      <guid isPermaLink="true">https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-pharmaceuticals-presents-positive-data-phase-1-study-tern-601-once-daily-oral</guid>
      <pubDate>Mon, 23 Jun 2025 04:00:00 GMT</pubDate>
      <description>Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024 Phase 2 FALCON clinical</description>
    </item>
    <item>
      <title>Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences</title>
      <link>https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-pharmaceuticals-participate-upcoming-june-investor-conferences-2025-05-29</link>
      <guid isPermaLink="true">https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-pharmaceuticals-participate-upcoming-june-investor-conferences-2025-05-29</guid>
      <pubDate>Thu, 29 May 2025 04:00:00 GMT</pubDate>
      <description>FOSTER CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage</description>
    </item>
    <item>
      <title>Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701</title>
      <link>https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-pharmaceuticals-selected-oral-presentation-european-hematology-association</link>
      <guid isPermaLink="true">https://6ix.com/company/terns-pharmaceuticals-inc/news/terns-pharmaceuticals-selected-oral-presentation-european-hematology-association</guid>
      <pubDate>Wed, 14 May 2025 04:00:00 GMT</pubDate>
      <description>Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance</description>
    </item>
  </channel>
</rss>